- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
- Interventions
- JDQ443, TNO155, tislelizumab
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 1,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Neoplasms of Respiratory and Intrathoracic Organs, Lung Neoplasm
- Interventions
- Bronchoscopy, Radial Probe Endobronchial Ultrasound
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphangioleiomyomatosis
- Interventions
- Sirolimus, Everolimus
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 20
- States / cities
- Stanford, California • Denver, Colorado • Jacksonville, Florida + 17 more
- Conditions
- Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancy
- Interventions
- Epigenetically Modified Autologous Tumor, Cyclophosphamide, Celecoxib
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Neoplasm
- Interventions
- Stereotactic Radiotherapy, Anatomic Pulmonary Resection
- Radiation · Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 17
- States / cities
- Long Beach, California • West Los Angeles, California • Bay Pines, Florida + 14 more
- Conditions
- Mesothelioma
- Interventions
- pemetrexed disodium, gemcitabine hydrochloride, carboplatin
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 115
- States / cities
- Norwich, Connecticut • Lewes, Delaware • Newark, Delaware + 79 more
- Conditions
- Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Orange, California • Sacramento, California
- Conditions
- Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer
- Interventions
- LY4175408, Pembrolizumab, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 15
- States / cities
- Stanford, California • Orlando, Florida • Sarasota, Florida + 11 more
- Conditions
- Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
- Interventions
- Ivosidenib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Thymoma and Thymic Carcinoma
- Interventions
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Other · Procedure
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Recurrent Colorectal Carcinoma, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy, Quality-of-Life Assessment, Therapeutic Conventional Surgery
- Drug · Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- Stereotactic radiosurgery
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Survey Administration, Volume Modulated Arc Therapy, Hippocampal-Avoidance Craniospinal Irradiation
- Procedure · Other · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- San Francisco, California • New York, New York • Seattle, Washington
- Conditions
- Malignant Pleural Mesothelioma, Mesothelioma
- Interventions
- Cisplatin, Methotrexate, Gemcitabine, Lung Cancer Symptom Scale for Mesothelioma Questionnaire
- Drug · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
- Interventions
- OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist
- Drug · Combination Product · Other
- Lead sponsor
- Epkin
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Santa Monica, California • Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
- Interventions
- Cetuximab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Newark, Delaware
- Conditions
- Head and Neck Cancer, Lung Cancer
- Interventions
- celecoxib, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Chapel Hill, North Carolina
- Conditions
- Neoplasms, Arteriovenous Malformation of Central Nervous System, Trigeminal Neuralgia
- Interventions
- SRS/SBRT
- Radiation
- Lead sponsor
- The Radiosurgery Society
- Other
- Eligibility
- Not listed
- Enrollment
- 50,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2030
- U.S. locations
- 13
- States / cities
- Colorado Springs, Colorado • Miami, Florida • Brunswick, Georgia + 10 more
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
- Interventions
- PF-08052666
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Interventions
- AU-007, Aldesleukin, Avelumab, Nivolumab
- Drug
- Lead sponsor
- Aulos Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 10
- States / cities
- Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more
- Conditions
- Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- PF-08098488
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Grand Rapids, Michigan • Nashville, Tennessee • San Antonio, Texas
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Quality-of-Life Assessment, Survey Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer
- Interventions
- SRK-181, anti-PD-(L)1 antibody therapy
- Biological
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Fullerton, California • La Jolla, California • Los Angeles, California + 14 more